The semaglutide weight loss dosage chart — and the biggest mistake people make reading it

The myth: a higher dose always means faster results

It is the most common misconception our prescribers encounter. People see the dosage chart, spot 2.4 mg at the top, and assume the goal is to get there as quickly as possible. The reality is the opposite. The reason semaglutide treatment begins at 0.25 mg (a dose far below what produces meaningful weight loss) is to let your digestive system adjust gradually. Nausea, bloating and stomach discomfort are most pronounced when the dose rises; a slow escalation reduces that sharply.

The STEP 1 trial, published in the New England Journal of Medicine, showed an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose. Those results came from the full protocol (including the escalation phase) not from patients who rushed to the top. Slowing down, or staying at an intermediate dose if side effects are troublesome, does not mean you have failed; it means the medicine is working the way it was designed to.

If you are curious about how individual dose levels behave, the detail on the 1 mg dose explains why some people plateau there and what a prescriber considers before moving up.

What the UK semaglutide dosage chart actually shows, mg, ml and the five steps

The standard semaglutide weight loss dosage chart for the UK lists five weekly injection doses in milligrams: 0.25, 0.5, 1.0, 1.7, and 2.4. Each pen delivers a fixed dose; the chart is not a dilution guide. The ml figure you sometimes see alongside the mg number refers to the volume injected by the auto-injector, a fixed measurement per pen, not something you adjust yourself. If you come across a dosage chart expressed in mg/ml, it is describing concentration rather than the dose you receive, which is why the numbers look so different.

The MHRA approved a higher maintenance dose in January 2026: 7.2 mg weekly, initially delivered as three 2.4 mg pens and later via a dedicated single-dose pen approved in April 2026. This extended schedule is an option for eligible adults, not an automatic next step. A prescriber assesses whether the higher dose is clinically appropriate. You can read more about how the 7.2 mg dose fits into the semaglutide schedule and what the evidence shows so far.

A quick check worth doing before your consultation: open your current prescription or medication box and confirm whether the dose printed matches the step you are on. One minute, and it removes a surprisingly common source of confusion when patients transfer between providers.

Who the licensed dosage schedule applies to, and where the NHS draws the line

The licensed Wegovy dosage schedule applies to adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Semaglutide for weight loss is not licensed for anyone under 18, and it is not recommended during pregnancy, while breastfeeding, or when trying to conceive.

On the NHS, NICE's appraisal of Wegovy (TA875) recommends it only within a specialist weight management service and for a maximum of two years, criteria that mean many people who are clinically eligible still face long waiting lists or do not meet the service-tier threshold. Private treatment through a regulated pharmacy offers an alternative route for those who are eligible but cannot access the NHS pathway. You can explore what a private consultation involves and check your eligibility without commitment.

The dosing picture for people without diabetes is slightly different in context from those who use semaglutide for blood-sugar management, worth understanding if you are trying to make sense of conflicting information online.

What a dosage chart cannot tell you

No chart can tell you which step you should be on right now, when to increase, or whether a side effect you experienced at 1.0 mg means you should hold there longer. Those decisions sit with a prescriber who has seen your full clinical picture. The chart is a framework; the prescription is personal.

Oral semaglutide for weight loss now exists too, approved by the MHRA in June 2026 as Wegovy tablets, with its own escalation schedule (1.5 mg, 4 mg, 9 mg, 25 mg) that looks nothing like the injection chart. If you are comparing options, the full Wegovy dose guide covers both formats in one place.

For a broader look at how semaglutide compares to other licensed weight-loss medicines, the weight loss treatment overview sets out what is currently available in the UK and how they differ. And if something specific about your situation is not answered here, the FAQs cover the questions our prescribers hear most often.

Check your eligibility with a free consultation, a real prescriber reviews every application the same day it arrives.